View Single Post
  #5  
Old Tue Nov 9, 2010, 07:42 AM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Campath

Hi Cheri,
If you look at the links in Greg's post you will see that the trials are for patients with low risk MDS. You know I have seen still higher response rates (83 %) in patients treated with Vidaza and histone deacetylase inhibitors.
Kind regards
Birgitta-A
Reply With Quote